The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases

European Journal of Pharmacology

Volumn 677, Issue 1-3, 2012, Pages 22-30

  Lee, Jong Suk ^a   Kang, Youra ^a   Kim, Jong Tae ^a   Thapa, Dinesh ^a   Lee, Eung Seok ^a   Kim, Jung Ae ^a  

^a Yeungnam University   (South Korea)

Author keywords

1,3 Diphenyl propenone; Angiogenesis; Anti tumor; NF B; pERK; Receptor tyrosine kinase

Indexed keywords

1 FURAN 2 YL 3 PHENYL PROPENONE; 1,3 DIPHENYLPROPENONE; 3 [[4 (DIMETHYLAMINO)PHENYL]METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 3 PHENYL 1 THIOPHEN 2 YL PROPENONE; 3 PHENYL 1 THIOPHEN 3 YL PROPENONE; ANGIOPOIETIN RECEPTOR; CHALCONE; ENZYME INHIBITOR; EPHRIN RECEPTOR B2; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KETONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PHENYLPROPENONE DERIVATIVE; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HT29 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROPIOPHENONES; PROTEIN KINASE INHIBITORS; REACTIVE OXYGEN SPECIES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856261035     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.12.012     Document Type: Article

References (36)

1. M.R. Abid, Z. Kachra, K.C. Spokes, and W.C. Aird NADPH oxidase activity is required for endothelial cell proliferation and migration FEBS Lett. 486 2000 252 256
2. A. Basnet, P. Thapa, R. Karki, Y. Na, Y. Jahng, B.S. Jeong, T.C. Jeong, C.S. Lee, and E.S. Lee 2,4,6-Trisubstituted pyridines: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship Bioorg. Med. Chem. 15 2007 4351 4359 (Pubitemid 46777301)
3. D.I. Batovska, and I.T. Todorova Trends in utilization of the pharmacological potential of chalcones Curr. Clin. Pharmacol. 5 2010 1 29
4. Z.W. Cai, Y. Zhang, R.M. Borzilleri, L. Qian, S. Barbosa, D. Wei, X. Zheng, L. Wu, J. Fan, Z. Shi, B.S. Wautlet, S. Mortillo, R. Jeyaseelan Sr., D.W. Kukral, A. Kamath, P. Marathe, C. D'Arienzo, G. Derbin, J.C. Barrish, J.A. Robl, J.T. Hunt, L.J. Lombardo, J. Fargnoli, and R.S. Bhide Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f] [1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215) J. Med. Chem. 51 2008 1976 1980 (Pubitemid 351438880)
5. Y. Cao, and Q. Liu Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis Adv. Cancer Res. 97 2007 203 224 (Pubitemid 46528989)
6. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
7. S.I. Chisalita, and H.J. Arnqvist Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells Am. J. Physiol. Endocrinol. Metab. 286 2004 E896 E901
8. R. Colavitti, G. Pani, B. Bedogni, R. Anzevino, S. Borrello, J. Waltenberger, and T. Galeotti Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR J. Biol. Chem. 277 2002 3101 3108 (Pubitemid 34953170)
9. R.W. Colman, R.A. Pixley, I.M. Sainz, J.S. Song, I. Isordia-Salas, S.N. Muhamed, J.A. Powell Jr., and S.A. Mousa Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen J. Thromb. Haemost. 1 2003 164 170
10. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867 (Pubitemid 36019639)
11. N. Ferrara Role of vascular endothelial growth factor in regulation of physiological angiogenesis Am. J. Physiol. Cell Physiol. 280 2001 C1358 C1366
12. I.J. Fidler, R.K. Singh, J. Yoneda, R. Kumar, L. Xu, Z. Dong, D.R. Bielenberg, M. McCarty, and L.M. Ellis Critical determinants of neoplastic angiogenesis Cancer J. 6 Suppl 3 2000 S225 S236
13. R. Giavazzi, B. Sennino, D. Coltrini, A. Garofalo, R. Dossi, R. Ronca, M.P. Tosatti, and M. Presta Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis Am. J. Pathol. 162 2003 1913 1926 (Pubitemid 36613049)
14. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364 (Pubitemid 26272076)
15. Y. Jahng, L.X. Zhao, Y.S. Moon, A. Basnet, E.K. Kim, H.W. Chang, H.K. Ju, T.C. Jeong, and E.S. Lee Simple aromatic compounds containing propenone moiety show considerable dual COX/5-LOX inhibitory activities Bioorg. Med. Chem. Lett. 14 2004 2559 2562 (Pubitemid 38515702)
16. S.C. Jones Relative thromboembolic risks associated with COX-2 inhibitors Ann. Pharmacother. 39 2005 1249 1259 (Pubitemid 40943178)
17. J.A. Kim, K.B. Cho, M.R. Kim, B.C. Park, S.K. Kim, M.Y. Lee, and K.W. Kang Decreased production of vascular endothelial growth factor in adriamycin-resistant breast cancer cells Cancer Lett. 268 2008 225 232
18. J. Kroll, and J. Waltenberger The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells J. Biol. Chem. 272 1997 32521 32527 (Pubitemid 28011938)
19. B. Kwabi-Addo, M. Ozen, and M. Ittmann The role of fibroblast growth factors and their receptors in prostate cancer Endocr. Relat. Cancer 11 2004 709 724 (Pubitemid 40065546)
20. S. Lamy, D. Gingras, and R. Beliveau Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation Cancer Res. 62 2002 381 385 (Pubitemid 34106408)
21. E.S. Lee, B.C. Park, S.H. Paek, Y.S. Lee, A. Basnet, D.Q. Jin, H.G. Choi, C.S. Yong, and J.A. Kim Potent analgesic and anti-inflammatory activities of 1-furan-2-yl-3-pyridin-2-yl-propenone with gastric ulcer sparing effect Biol. Pharm. Bull. 29 2006 361 364 (Pubitemid 43200911)
22. M.S. Lyons, B. Bell, D. Stainier, and K.G. Peters Isolation of the zebrafish homologues for the tie-1 and tie-2 endothelium-specific receptor tyrosine kinases Dev. Dyn. 212 1998 133 140 (Pubitemid 28208414)
23. N. Maulik Redox signaling of angiogenesis Antioxid. Redox Signal. 4 2002 805 815 (Pubitemid 35246944)
24. N.H. Nam, Y. Kim, Y.J. You, D.H. Hong, H.M. Kim, and B.Z. Ahn Cytotoxic 2′,5′-dihydroxychalcones with unexpected antiangiogenic activity Eur. J. Med. Chem. 38 2003 179 187 (Pubitemid 36288472)
25. B.C. Park, D. Thapa, Y.S. Lee, M.K. Kwak, E.S. Lee, H.G. Choi, C.S. Yong, and J.A. Kim 1-Furan-2-yl-3-pyridin-2-yl-propenone inhibits the invasion and migration of HT1080 human fibrosarcoma cells through the inhibition of proMMP-2 activation and down regulation of MMP-9 and MT1-MMP Eur. J. Pharmacol. 567 2007 193 197 (Pubitemid 46976892)
26. B.C. Park, S.Y. Park, J.S. Lee, S.A. Mousa, J.T. Kim, M.K. Kwak, K.W. Kang, E.S. Lee, H.G. Choi, C.S. Yong, and J.A. Kim The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling Vascul. Pharmacol. 50 2009 123 131
27. K. Pietras, and A. Ostman Hallmarks of cancer: interactions with the tumor stroma Exp. Cell Res. 316 2010 1324 1331
28. M. Pilatova, L. Varinska, P. Perjesi, M. Sarissky, L. Mirossay, P. Solar, A. Ostro, and J. Mojzis In vitro antiproliferative and antiangiogenic effects of synthetic chalcone analogues Toxicol. In Vitro 24 2010 1347 1355
29. F. Riedel, K. Gotte, M. Li, K. Hormann, and J.R. Grandis EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration Int. J. Oncol. 21 2002 11 16
30. G. Spektor, and V. Fuster Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk-where are we now? Nat. Clin. Pract. Cardiovasc. Med. 2 2005 290 300 (Pubitemid 40852634)
31. D. Thapa, J.S. Lee, S.W. Heo, Y.R. Lee, K.W. Kang, M.K. Kwak, H.G. Choi, and J.A. Kim Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis Eur. J. Pharmacol. 650 2011 64 71
32. T.C. Tran, B. Sneed, J. Haider, D. Blavo, A. White, T. Aiyejorun, T.C. Baranowski, A.L. Rubinstein, T.N. Doan, R. Dingledine, and E.M. Sandberg Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish Cancer Res. 67 2007 11386 11392 (Pubitemid 350248566)
33. M. Ushio-Fukai, Y. Tang, T. Fukai, S.I. Dikalov, Y. Ma, M. Fujimoto, M.T. Quinn, P.J. Pagano, C. Johnson, and R.W. Alexander Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis Circ. Res. 91 2002 1160 1167 (Pubitemid 36076365)
34. C.S. Williams, M. Tsujii, J. Reese, S.K. Dey, and R.N. DuBois Host cyclooxygenase-2 modulates carcinoma growth J. Clin. Invest. 105 2000 1589 1594 (Pubitemid 30390309)
35. E.B. Yang, Y.J. Guo, K. Zhang, Y.Z. Chen, and P. Mack Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives Biochim. Biophys. Acta 1550 2001 144 152 (Pubitemid 34038000)
36. K. Yoshimoto, S. Nishizawa, H. Koshino, Y. Sato, N. Teramae, and M. Maeda Assignment of hydrogen-bond structure in a ligand-nucleobase complex inside duplex DNA: combined use of quantum chemical calculations and 15N NMR experiments Nucleic Acids Symp. Ser. (Oxf.) 2005 255 256